GEN Exclusives

More »

GEN News Highlights

More »
Jun 26, 2007

Goodwin Biotechnology to Produce Neogenix’ mAb for Pancreatic Cancer

  • Neogenix Oncology and Goodwin Biotechnology entered into an agreement for process development and manufacturing of Neogenix’ first therapeutic product. NPC-1C is a mAb intended for the treatment of advanced pancreatic cancer.

    Neogenix expects to begin Phase I and Phase II trials of the product during the first half of 2008.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Genetic Testing for Children and Adolescents

Do you think parents should have predictive testing carried out on their children and adolescents?

More »